Posted in M&A / Deals Roche and C4 Therapeutics to advance degrader-antibody conjugates research April 10, 2026 Pharmaceutical Technology Roche has signed a new collaboration deal with C4 Therapeutics to jointly advance DACs research to introduce a new therapeutic modality for cancer. M&A / DealsOncologyRead full story